Seres therapeutics reports q2 2020 financial results

Seres therapeutics reports second quarter 2020 financial results and provides business updates.seres therapeutics - topline data from ser-109 phase 3 study in recurrent c. difficile infection expected in august 2020.cash resources are expected to fund operating expenses and capital expenditure requirements, into q2 of 2021.does not intend to meet with investors until pending ser-109 phase 3 study results are reported.qtrly total revenue $6.05 million versus $12.53 million.qtrly loss per share $0.28.q2 earnings per share view $-0.26, revenue view $9.5 million -- refinitiv ibes data.
MCRB Ratings Summary
MCRB Quant Ranking